NCT02595424 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 63
- units
- Participants
- groups
- description
- Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Temozolomide: Given PO
- id
- BG000
- title
- Arm A (Capecitabine, Temozolomide)
- description
- Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Cisplatin: Given IV Etoposide: Given IV Laboratory Biomarker Analysis: Correlative studies
- id
- BG001
- title
- Arm B (Cisplatin, Carboplatin, Etoposide)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 28
- upper Limit
- 81
- value
- 66
- group Id
- BG001
- lower Limit
- 34
- upper Limit
- 77
- value
- 62
- group Id
- BG002
- lower Limit
- 28
- upper Limit
- 81
- value
- 65
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 25
- title
- Female
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 38
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 53
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Eligible patients
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 63
- units
- Participants
- groups
- description
- Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Capecitabine: Given PO Laboratory Biomarker Analysis: Correlative studies Temozolomide: Given PO
- id
- BG000
- title
- Arm A (Capecitabine, Temozolomide)
- description
- Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Carboplatin: Given IV Cisplatin: Given IV Etoposide: Given IV Laboratory Biomarker Analysis: Correlative studies
- id
- BG001
- title
- Arm B (Cisplatin, Carboplatin, Etoposide)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 28
- upper Limit
- 81
- value
- 66
- group Id
- BG001
- lower Limit
- 34
- upper Limit
- 77
- value
- 62
- group Id
- BG002
- lower Limit
- 28
- upper Limit
- 81
- value
- 65
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 25
- title
- Female
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 38
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 53
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Eligible patients
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle